SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 2
    Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992; 10: 706717.
  • 3
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334: 16.
  • 4
    Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335: 19501955.
  • 5
    Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000; 18: 106115.
  • 6
    Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 31943200.
  • 7
    Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9: 389393.
  • 8
    Parmar MK, Ledermann JA, Colombo N, et al. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361: 20992106.
  • 9
    Ozols RF. Treatment of recurrent ovarian cancer: increasingoptions—“recurrent” results. J Clin Oncol. 1997; 15: 21772180.
  • 10
    Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol. 1997; 8: 963968.
  • 11
    Lewin SN, Buttin BM, Powell MA, et al. Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol. 2005; 99: 262266.
  • 12
    Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 13441352.
  • 13
    Brumley RD. Future of end-of-life care: the managed care organization perspective. J Palliat Med. 2002; 5: 263270.
  • 14
    Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004; 22: 31203125.
  • 15
    Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomalencapsulation. J Clin Oncol. 1997; 15: 987993.
  • 16
    Gordon AN, Granai CO, Rose PG, et al. Phase II study ofliposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000; 18: 30933100.
  • 17
    Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001; 81: 206212.
  • 18
    Markman M, Kennedy A, Webster K, et al. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000; 78: 369372.
  • 19
    Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001; 82: 323328.
  • 20
    Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 33123322.
  • 21
    Hensley ML, Hoppe B, Leon L, et al. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecol Oncol. 2001; 82: 464469.
  • 22
    O'Byrne KJ, Bliss P, Graham JD, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol. 2002; 21. Abstract 808.
  • 23
    Rose PG, Mossbruger K, Fusco N, et al. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol. 2003; 88: 1721.
  • 24
    Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006; [Epub ahead of print].
  • 25
    Tewari D, Monk BJ, Hunter M et al. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs. 2004; 22: 475480.
  • 26
    Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996; 14: 15521557.
  • 27
    Swisher EM, Mutch DG, Rader JS, et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997; 66: 480486.
  • 28
    Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 2002; 38: 5763.
  • 29
    Levy T, Inbar M, Menczer J, et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol. 2004; 95: 686690.
  • 30
    Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998; 16: 33453352.
  • 31
    ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997; 15: 21832193.
  • 32
    Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998; 16: 22332237.
  • 33
    Gronlund B, Hansen HH, Hogdall C, et al. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer. 2002; 95: 16561662.
  • 34
    Ozols RF. Update on the management of ovarian cancer. Cancer J. 2002; 8: S1521.
  • 35
    Ozols RF, Bundy BN, Greer BE, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 31943200.
  • 36
    Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am. 2003; 17: 957968.
  • 37
    Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000; 5: 2635.
  • 38
    Pauker SG, Kassirer JP. Decision analysis. N Engl J Med. 1987; 316: 250258.
  • 39
    Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998; 16: 33453352.
  • 40
    Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998; 16: 405410.
  • 41
    Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996; 63: 8993.
  • 42
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992; 146: 473481.